Navigation Links
MAQUET Cardiovascular Receives 510(k) Clearance to Market the CARDIOHELP System in U.S.
Date:4/28/2011

ms with an option for patients who need cardiac and/or respiratory support during inter- and intra-hospital transport," said Raoul Quintero, President and CEO, MAQUET Cardiovascular U.S. Sales.  "In its most complete configuration, the CARDIOHELP System allows important blood parameters to be monitored during life support, ensuring the patient's safety."  

"Today is a very gratifying and exciting day for me and the rest of the team that played an integral role in developing CARDIOHELP from concept through today's approval," said Christian Keller, President of MAQUET Cardiovascular U.S. "CARDIOHELP is another example of our ongoing commitment to providing customers the latest and most innovative technology that enables the Gold Standard in patient care."

CARDIOHELP

The individual operating modes and disposables of the CARDIOHELP System make it suitable for conditions in which cardiac and/or respiratory support is needed. The CARDIOHELP System offers several applications to support patients who require veno-venous life support or veno-arterial life support; it can also be used during open heart surgery and for extracorporeal carbon dioxide (CO2) removal up to six hours.

Veno-venous life support, or respiratory assistance for lung disorders, is primarily used when the heart is still able to pump blood through the circulatory system without any additional support, as in the case of acute respiratory failure or a massive pulmonary embolism. The blood is removed from the jugular vein or a femoral vein for enrichment with oxygen, after which it is returned to a vein.

Veno-arterial life support is used with patients whose hearts are not adequately supporting their circulation or have stopped, which may occur with a myocardial infarction. It is vital to ensure cardiopulmonary support as early as possible to prevent organ damage. The CARDIOHELP System can help increase survival by enabling revascularization by means of cat
'/>"/>

SOURCE MAQUET Cardiovascular
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MAQUET Cardiovascular Launches New VASOVIEW 6 PRO Endoscopic Vessel Harvesting System
2. MAQUET Cardiovascular Launches Advanced VASOVIEW Technology for Endoscopic Vessel Harvesting Procedures in Cardiac Surgery
3. MAQUET Cardiovascular Introduces New VASOSHIELD Pressure Controlling Syringe to Help Preserve Graft Integrity for Coronary Artery Bypass Surgery Patients
4. MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices
5. MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices
6. Reportlinker Adds Global Cardiovascular Surgery Devices Market Trends and Future Forecast (2009 - 2014)
7. New Research Links Restless Legs Syndrome (RLS) to Cardiovascular Disease
8. DMC Cardiovascular Institute First in Midwest to Implant New "Protecta" Defibrillator in a Cardiac Patient
9. Medstreaming Launches Fully Integrated Cardiovascular PACS and Certified EMR With Electronic Whiteboard at ACC
10. Siemens Demonstrates Strategy for Sustainable Cardiovascular Care
11. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Ill. , July 1, 2015 ... nationwide group of state and regional professional rheumatology ... survey of rheumatologists that explored perceptions of biosimilars ... on patients. Biosimilars are medicines ... biologic medicines. They are notably different from generic ...
(Date:7/1/2015)... 1, 2015 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... corporate presentation at the Cantor Fitzgerald Healthcare Conference in ... Russell Cox , executive vice president and chief ... a business and financial update on Wednesday, July 8, 2015 ... A live audio webcast of the presentation may be ...
(Date:7/1/2015)... , July 1, 2015 ContraVir Pharmaceuticals, ... on the development and commercialization of targeted antiviral therapies, ... Fitzgerald Inaugural Healthcare Conference taking place in ... at Le Parker Meridien Hotel. ... overview of the Company,s business during his live presentation ...
Breaking Medicine Technology:Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 2ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2
... 3 Glufosfamide and Phase 2 Glufosfamide Plus ... Gemcitabine Clinical Trials to be Presented, REDWOOD CITY, Calif., ... announced two presentations,regarding its oncology product candidate glufosfamide. The presentations,will ... held,September 23 to 27, 2007, at the International Conference Center ...
... First Hsp90 Inhibitor to Enter Registration Trials, HAYWARD, ... ) today announced that it has successfully,reached a binding ... the design of its TIME-1 clinical trial, a pivotal ... treatment for patients with,multiple myeloma. Through the FDA,s Special ...
Cached Medicine Technology:Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO) 2Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO) 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 2Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 4Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 5Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 6Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 7
(Date:7/1/2015)... ... July 01, 2015 , ... OncLive® ... Corporation of America (HCA), as it further expands its Strategic Alliance Partnership Program ... With this new partnership, OncLive’s editorial and marketing teams will collaborate with Sarah ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... training leaders Lora Posey (Manager, National Sales Training and Development) and Chuck Corso ... Network (LTEN) Conference in Phoenix, AZ. LTEN brings together learning and development professionals ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... The 28th ... rain or shine Saturday, July 11, 2015, at 6 p.m. in Pugh Bourne Park, ... and includes pony rides, a petting zoo, an Elvis impersonator, a silent auction and ...
(Date:7/1/2015)... , ... July 01, 2015 , ... As if mood ... found in a significant number of women: leg pain. Northeast Houston Vein Center is ... pain, a symptom of venous reflux disease, is underdiagnosed and often overlooked. Many women ...
(Date:7/1/2015)... ... July 01, 2015 , ... “Well-meaning social policy ... a Professor in FIU’s School of International and Public Affairs. , ... participated in the National Survey on Drug Use and Health, which is a ...
Breaking Medicine News(10 mins):Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 2Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 4Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2
... US healthcare system are growing, warns an expert in this ... industrialized nation without universal health insurance, //writes Karen Davis, President ... has deteriorated in recent years. The number of uninsured people ... million in 2005. ,Gaps in coverage lead to ...
... Dr. K. John McLaughlin and colleagues report on their ... blood stem cells in mice. //Uniparental embryonic stem cells ... cells, as they have several advantages over embryonic stem ... known as therapeutic cloning). ,Normal mammalian embryos ...
... granting of exclusive rights to commercial companies over clinical ... versions of// life-saving medicines and harm public health, says ... an Essay in PLoS Medicine. ,Writing in ... could impede efforts to produce generic versions of the ...
... pioneering doctor, currently under house arrest in Henan province, to ... her work on behalf// of HIV/AIDS patients, it was confirmed ... to travel," retired professor Gao Yaojie, 79, told DPA from ... under house arrest for two weeks. ,Gao has ...
... A new anti-cancer drug called pertuzumab, shows promise in ... prostate cancer.// ,A new class of targeted ... (HER) receptor family shows promise in prolonging the lives ... study shows. The drug, a molecular targeted compound called ...
... children who live in daily circumstances of potential trauma ... treatment that focuses on// strengthening parent-child bonds, according to ... at the American Association for the Advancement of Science ... how children’s emotional and moral development is affected by ...
Cached Medicine News:Health News:US Health System Getting Worse, Says Expert 2Health News:New Hope for Regenerative Medicine 2Health News:New Hope for Regenerative Medicine 3Health News:Drug Companies Should Not Have a Monopoly Over Clinical Trial Data 2Health News:New Drug Promises Prolonged Survival in Prostate Cancer Patients 2Health News:New Drug Promises Prolonged Survival in Prostate Cancer Patients 3Health News:Treat Childhood Trauma by Building on Parental Memories of Loving Care 2Health News:Treat Childhood Trauma by Building on Parental Memories of Loving Care 3Health News:Treat Childhood Trauma by Building on Parental Memories of Loving Care 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: